In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexter Yan

Senior Reporter

Shanghai-based Dexter Yan is a senior writer covering Chinas surging pharma industry on the APAC Pharma news team. With a keen interest in commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest From Dexter Yan

Shanghai Kick-Starts New Consortium To Develop First-In-Class Cancer Drugs

A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.

China Financing

Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Deal Watch Business Strategies

Coronavirus Update: Brii Files US EUA For Antibody Combo

Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral. 

Coronavirus COVID-19 Biologics

Transcenta Among Chinese Biotechs Raising Funds Through Public Offerings, Private Financings

A combined $447.2m are raised through a Hong Kong initial public offering (IPO) and venture capital and private equity deals.

China Financing

Coronavirus Update: China Firms Form mRNA Vaccine JV

Two Chinese firms join forces to develop mRNA vaccines; UK and India resolve issues over the travel of vaccinated individuals; and Scrip speaks to the CEO of a Canadian firm developing mRNA vaccines.

Vaccines Coronavirus COVID-19

Chinese Investors Wary Of In-Licensing-Only Biotechs After IPO Setback

The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.

China Financing
See All
UsernamePublicRestriction

Register